MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from public
offering
$126,250K
Proceeds from second
amended term loan
$25,000K
Proceeds from issuance of
pre-funded warrants
$23,249K
Proceeds from exercise of
stock options
$277K
Net cash provided by
financing activities
$141,660K
Effect of exchange rate
changes on cash
$1K
Canceled cashflow
$33,116K
Net decrease in cash
and cash...
-$13,539K
Canceled cashflow
$141,661K
Proceeds from maturities
of marketable...
$43,043K
Accrued expenses and
other current...
$4,386K
Share-based compensation
expense
$2,803K
Accretion of marketable
securities
-$2,054K
Loss on
extinguishment of debt
-$488K
Non-cash lease expense
-$246K
Depreciation of property and
equipment
$189K
Non-cash interest
expense
$183K
Unrealized foreign
currency losses
-$69K
Lease liabilities
$39K
Repayment of amended term
loan principal
$23,053K
Payment of issuance cost
associated with public...
$9,448K
Payment of issuance
costs associated with...
$615K
Net cash used in
investing activities
-$126,297K
Canceled cashflow
$43,043K
Net cash used in
operating activities
-$28,903K
Canceled cashflow
$10,457K
Purchases of marketable
securities
$169,187K
Purchases of property and
equipment
$153K
Net loss
-$29,752K
Accounts payable
-$4,270K
something is missing
-$2,645K
Prepaid expenses and
other assets
$2,422K
Investment tax credit
receivable
$271K
Back
Back
Cash Flow
source: myfinsight.com
enGene Holdings Inc. (ENGNW)
enGene Holdings Inc. (ENGNW)